When employingpre-clinical models of trastuzumab-refractory HER2-overexpressing breast cancer cultures andxenografts, we were able to confirm that the transcriptional screening of the autophagy interactomecan accurately identify autophagic pathway genes that operate as a primary mechanism of trastuzumabresistance in breast carcinoma cells. This evidence concerns the gene ERBB2 and breast cancer.